Contravisory Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Contravisory Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.33M	Buy	+10,147	New	+$6.91M	1.12%	38
2023 Q3	–	Sell	-473	Closed	-$340K	–	376
2023 Q2	$340K	Buy	+473	New	+$365K	0.09%	158
2018 Q3	–	Sell	-14	Closed	-$5K	–	357
2018 Q2	$5K	Hold	14	–	–	﹤0.01%	295
2018 Q1	$5K	Buy	+14	New	+$4.87K	﹤0.01%	298
2016 Q1	–	Sell	-4	Closed	-$2K	–	225
2015 Q4	$2K	Buy	+4	New	+$2.17K	﹤0.01%	186

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Contravisory Investment Management's REGN Position: Q2 2026 in Review

Contravisory Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 10,147 shares worth $6.33M. The stake represents 1.12% of the portfolio and ranks #38 among its holdings. This is a return to the name: Contravisory Investment Management previously reported a position in REGN as recently as Q2 2023.

Contravisory Investment Management first reported a position in REGN in Q4 2015 and has held it in 5 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Contravisory Investment Management held 10,147 shares of Regeneron Pharmaceuticals worth $6.33M as of Q2 2026.
Regeneron Pharmaceuticals was a new Contravisory Investment Management position in Q2 2026.
Regeneron Pharmaceuticals made up 1.12% of Contravisory Investment Management's portfolio in Q2 2026, its #38 holding.
Contravisory Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 5 quarters since.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.